|
1
|
Weiss SW, Goldblum JR and Folpe AL:
Enzinger and Weiss's Soft Tissue Tumors. 6th edition. Elsevier,
Philadelphia, pp1176, 2014.
|
|
2
|
WHO classification of tumors: Soft Tissue
and Bone Tumors. 5th edition. IARC, 2020.
|
|
3
|
Meis-Kindblom JM, Bjerkehage B, Böhling T,
Domanski H, Halvorsen TB, Larsson O, Lilleng P, Myhre-Jensen O,
Stenwig E, Virolainen M, et al: Morphologic review of 1000 soft
tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register:
The peer-review committee experience. Acta Orthop Scand Suppl.
285:18–26. 1999.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Italiano A, Di Mauro I, Rapp J, Pierron G,
Auger N, Alberti L, Chibon F, Escande F, Voegeli AC, Ghnassia JP,
et al: Clinical effect of molecular methods in sarcoma diagnosis
(GENSARC): A prospective, multicentre, observational study. Lancet
Oncol. 17:532–538. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ottaiano A, De Chiara A, Fazioli F,
Talamanca AA, Mori S, Botti G, Milano A and Apice G: Biological
prognostic factors in adult soft tissue sarcoma. Anticancer Res.
25:4519–4526. 2005.PubMed/NCBI
|
|
6
|
Italiano A, Le Cesne A, Mendiboure J, Blay
JY, Piperno-Neumann S, Chevreau C, Delcambre C, Penel N, Terrier P,
Ranchere-Vince D, et al: Prognostic factors and impact of adjuvant
treatments on local and metastatic relapse of soft-tissue sarcoma
patients in the competing risks setting. Cancer. 120:3361–3369.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Coindre JM: Grading of soft tissue
sarcomas: Review and update. Arch Pathol Lab Med. 130:1448–1453.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gronchi A, Frustaci S, Mercuri M, Martin
J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R,
Stacchiotti S, et al: Short, full-dose adjuvant chemotherapy in
high-risk adult soft tissue sarcomas: A randomized clinical trial
from the Italian Sarcoma Group and the Spanish Sarcoma Group. J
Clin Oncol. 30:850–856. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Raj S, Miller LD and Triozzi PL:
Addressing the adult soft tissue sarcoma microenvironment with
intratumoral immunotherapy. Sarcoma. 12(9305294)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Budczies J, Mechtersheimer G, Denkert C,
Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Johrens K, Endris
V, Lier A, et al: PD-L1 (CD274) copy number gain, expression, and
immune cell infiltration as candidate predictors for response to
immune checkpoint inhibitors in soft-tissue sarcoma.
Oncoimmunology. 6(e1279777)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sorbye SW, Kilvaer T, Valkov A, Donnem T,
Smeland E, AlShibli K, Bremnes RM and Busund LT: Prognostic impact
of lymphocytes in soft tissue sarcomas. PLoS One.
6(e14611)2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cesano A: nCounter(®) pancancer
immune profiling panel (Nanostring technologies, Inc., Seattle WA).
J Immunother Cancer. 3(42)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kulangara K, Zhang N, Corigliano E,
Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J,
et al: Clinical utility of the combined positive score for
programmed death ligand-1 expression and the approval of
Pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med.
143:330–337. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hashimoto K, Nishimura S, Hara Y, Oka N,
Tanaka H, Iemura S and Akagi M: Clinical outcomes of patients with
primary malignant bone and soft tissue tumor aged 65 years or
older. Exp Ther Med. 17:888–894. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wardelmann E, Schildhaus HU,
Merkelbach-Bruse S, Hartmann W, Reichardt P, Hohenberger P and
Büttner R: Soft tissue sarcoma: From molecular diagnosis to
selection of treatment. Pathological diagnosis of soft tissue
sarcoma amid molecular biology and targeted therapies. Ann Oncol.
21 (Suppl 7):vii265–vii269. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Reichardt P: Soft tissue sarcomas, a look
into the future: Different treatments for different subtypes.
Future Oncol. 10 (Suppl 8):S19–S27. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tap WD, Jones RL, Van Tine BA, Chmielowski
B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock
G, et al: Olaratumab and doxorubicin versus doxorubicin alone for
treatment of soft-tissue sarcoma: An open-label phase 1b and
randomised phase 2 trial. Lancet. 388:488–497. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chang KTE, Goytain A, Tucker T, Karsan A,
Lee CH, Nielsen TO and Ng TL: Development and evaluation of a
pan-sarcoma fusion gene detection assay using the NanoString
nCounter platform. J Mol Diagn. 20:63–77. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sykes SM: NCAM1 supports therapy
resistance and LSC function in AML. Blood. 133:2247–2248.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jiang C, Zhao W, Qin M, Jin M, Chang L and
Ma X: CD56-chimeric antigen receptor T-cell therapy for
refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case
report. Medicine (Baltimore). 98(e17572)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Enciu AM, Radu E, Popescu ID, Hinescu ME
and Ceafalan LC: Targeting CD36 as biomarker for metastasis
prognostic: How far from translation into clinical practice? Biomed
Res Int. 4(7801202)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Peng W, McKenzie JA and Hwu P:
Complementing T-cell function: An inhibitory role of the complement
system in T-cell-mediated antitumor immunity. Cancer Discov.
6:953–955. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Laitinen T, Ollikainen V, Lázaro C, Kauppi
P, de Cid R, Antó JM, Estivill X, Lokki H, Mannila H, Laitinen LA
and Kere J: Association study of the chromosomal region containing
the FCER2 gene suggests it has a regulatory role in atopic
disorders. Am J Respir Crit Care Med. 161:700–706. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li F, Aljahdali I and Ling X: Cancer
therapeutics using survivin BIRC5 as a target: What can we do after
over two decades of study? J Exp Clin Cancer Res.
38(368)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Becker JC, Andersen MH, Hofmeister-Müller
V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E,
Opitz A, et al: Survivin-specific T-cell reactivity correlates with
tumor response and patient survival: A phase-II peptide vaccination
trial in metastatic melanoma. Cancer Immunol Immunother.
61:2091–2103. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wing JB, Tanaka A and Sakaguchi S: Human
FOXP3+ regulatory T cell heterogeneity and function in
autoimmunity and cancer. Immunity. 50:302–316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
deLeeuw RJ, Kost SE, Kakal JA and Nelson
BH: The prognostic value of FoxP3+ tumor-infiltrating
lymphocytes in cancer: A critical review of the literature. Clin
Cancer Res. 18:3022–3029. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 27:186–192.
2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kang X, Li M, Zhu H, Lu X, Miao J, Du S,
Xia X and Guan W: DUSP4 promotes doxorubicin resistance in gastric
cancer through epithelial-mesenchymal trantision. Oncotarget.
8:94028–94039. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mahmoodi M, Nahvi H, Mahmoudi M, Kasaian
A, Mohagheghi MA, Divsalar K, Nahavandian B, Jafari A, Ansarpour B,
Moradi B, et al: HLA-DRB1,-DQA1 and -DQB1 allele and haplotype
frequencies in female patients with early onset breast cancer.
Pathol Oncol Res. 18:49–55. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shen FF, Pan Y, Li JZ, Zhao F, Yang HJ, Li
JK, Gao ZW, Su JF, Duan LJ, Lun SM, et al: High expression of
HLA-DQA1 predicts poor outcome in patients with esophageal squamous
cell carcinoma in Northern China. Medicine (Baltimore).
98(e14454)2019.PubMed/NCBI View Article : Google Scholar
|
